We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
(-16%)
Cap. Flow
-$34.7M
Cap. Flow
% of AUM
-23.28%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$2.73M |
| 2 |
Pfizer
PFE
|
+$2.42M |
| 3 |
argenx
ARGX
|
+$2.33M |
| 4 |
VYNE Therapeutics
VYNE
|
+$2.08M |
| 5 |
Invesco NASDAQ 100 ETF
QQQM
|
+$1.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$3.38M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$2.95M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$2.75M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$2.58M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.47% |
| 2 | Real Estate | 11.94% |
| 3 | Financials | 4.93% |
| 4 | Consumer Discretionary | 2.41% |
| 5 | Industrials | 2.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Microbot Medical
MBOT
$120M
| $164K | 0.11% |
100,000
| – | – |
|
127
American Airlines Group
AAL
$10B
| $162K | 0.11% |
11,819
-1,323
| -10% | -$16.6K |
|
128
Humana
HUM
$47.8B
| $154K | 0.1% |
337
-37
| -10% | -$18.2K |
|
129
iShares MSCI Peru and Global Exposure ETF
EPU
$528M
| $140K | 0.09% |
4,065
-338
| -8% | -$10.3K |
|
130
Mercado Libre
MELI
$92.9B
| $138K | 0.09% |
88
+17
| +24% | +$24.1K |
|
131
Hershey
HSY
$34.8B
| $136K | 0.09% |
731
-103
| -12% | -$19.5K |
|
132
iShares MSCI Mexico ETF
EWW
$1.88B
| $134K | 0.09% |
1,968
-319
| -14% | -$19.3K |
|
133
iShares MSCI India ETF
INDA
$6.78B
| $132K | 0.09% |
2,705
-502
| -16% | -$22.8K |
|
134
DraftKings
DKNG
$12.1B
| $130K | 0.09% |
3,694
+1,979
| +115% | +$66.2K |
|
135
iShares MSCI Poland ETF
EPOL
$661M
| $130K | 0.09% |
5,728
-1,636
| -22% | -$33.8K |
|
136
iShares 7-10 Year Treasury Bond ETF
IEF
$47.4B
| $129K | 0.09% |
+1,340
| New | +$124K |
|
137
iShares MSCI Brazil ETF
EWZ
$8.98B
| $128K | 0.09% |
3,660
-911
| -20% | -$29.5K |
|
138
Lennar Class A
LEN
$20B
| $128K | 0.09% |
886
-104
| -11% | -$12.5K |
|
|
GREK
139
Global X MSCI Greece ETF
GREK
$279M
| $123K | 0.08% |
3,328
-425
| -11% | -$15K |
|
140
iShares MSCI Sweden ETF
EWD
$513M
| $121K | 0.08% |
+3,072
| New | +$107K |
|
141
iShares MSCI Taiwan ETF
EWT
$9.8B
| $118K | 0.08% |
2,556
-537
| -17% | -$24.9K |
|
142
iShares MSCI Switzerland ETF
EWL
$2.13B
| $118K | 0.08% |
2,436
+495
| +26% | +$22.1K |
|
143
iShares MSCI Netherlands ETF
EWN
$562M
| $117K | 0.08% |
+2,623
| New | +$106K |
|
144
iShares MSCI South Korea ETF
EWY
$21.7B
| $117K | 0.08% |
1,786
+173
| +11% | +$10.5K |
|
145
Star Holdings Shares of Beneficial Interest
STHO
$114M
| $116K | 0.08% |
7,744
| – | – |
|
146
iShares MSCI Germany ETF
EWG
$1.5B
| $116K | 0.08% |
3,894
+687
| +21% | +$18.7K |
|
|
PR
147
Permian Resources
PR
$17B
| $116K | 0.08% |
+8,497
| New | +$116K |
|
148
iShares MSCI France ETF
EWQ
$322M
| $115K | 0.08% |
2,945
-67
| -2% | -$2.45K |
|
149
iShares MSCI Italy ETF
EWI
$908M
| $114K | 0.08% |
3,355
-550
| -14% | -$17.5K |
|
150
iShares MSCI Austria ETF
EWO
$145M
| $113K | 0.08% |
5,231
-375
| -7% | -$7.64K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.
- AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
- AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
- AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
- AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
- AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
- AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.
Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.